Try a new search

Format these results:

Searched for:

in-biosketch:true

person:jacobi04

Total Results:

489


Entering the new era of therapy for HBV and HCV infections

Peters, Marion G; Perrillo, Robert P; Jacobson, Ira M; Ross, David B; Doo, Edward C; Murray, Jeffrey S; Wong, John B
PMID: 20398591
ISSN: 1533-7294
CID: 2568902

Pharmacogenetics of hepatitis C therapy [Comment]

Liapakis, Annmarie; Jacobson, Ira
PMID: 20136353
ISSN: 1744-8042
CID: 2568932

Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection

Zeremski, Marija; Dimova, Rositsa; Brown, Queenie; Jacobson, Ira M; Markatou, Marianthi; Talal, Andrew H
BACKGROUND: CXCR3-associated chemokines CXCL9-CXCL11 promote histologic progression in chronic hepatitis C virus (HCV) infection, as indicated by elevated intrahepatic levels of messenger RNA in patients with advanced inflammation and fibrosis. We evaluated the potential of peripheral chemokine levels to discriminate among patients with chronic HCV infection who had different stages of fibrosis. METHODS: Peripheral levels of CXCR3-associated chemokines were measured by enzyme-linked immunosorbent assay of plasma samples obtained from 93 patients with chronic HCV infection. Of the subjects, 79 (85%) were white, and 68 (73%) were infected with HCV genotype 1. RESULTS: Expression of all 3 chemokines, when analyzed as a group, was significantly associated with intrahepatic inflammation and fibrosis. Plasma levels of CXCL10 were significantly elevated in patients with advanced fibrosis, whereas CXCL9 levels were significantly elevated in patients with advanced inflammation. By proportional odds multivariate modeling, we observed an association between fibrosis and CXCL10 (P< .002) as well as between fibrosis and inflammation (P<.001). Of the individual parameters, the CXCL10 level was most useful in identifying patients with more-severe (stage 3-4) fibrosis. Discriminatory ability was improved by the combination of CXCL10 and CXCL9. CONCLUSIONS: The strong association between CXCR3-associated chemokines and fibrosis suggests that they may have promise as noninvasive markers of hepatic fibrosis in a predominantly white HCV genotype 1-infected population
PMID: 19848607
ISSN: 1537-6613
CID: 143769

GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES END OF TREATMENT RESPONSE AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS [Meeting Abstract]

McHutchison, John G; Jacobson, Ira M; Boyer, Thomas D; Schiff, Eugene R; Everson, Gregory T; Lee, William M; Pockros, Paul; Chasen, Richard M; Vierling, John M; Lawitz, Eric; Kugelmas, Marcelo; Tsai, Naoky; Armstrong, Brian R; Rodell, Timothy C; Apelian, David
ISI:000272340600070
ISSN: 0270-9139
CID: 2570192

GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A POLYMORPHISM UPSTREAM OF THE IL28B (=IFN lambda-3) GENE THAT IS STRONGLY ASSOCIATED WITH SVR IN PATIENTS WITH HCV-1 [Meeting Abstract]

Thompson, Alexander J; Muir, Andrew; Sulkowski, Mark S; Afdhal, Nezam H; Jacobson, Ira M; Esteban, Rafael; Poordad, Fred; McCone, Jonathan; Shiffman, Mitchell L; Galler, Greg; Lee, William M; Reindollar, Robert; King, John W; Kwo, Paul Y; Ghalib, Reem H; Freilich, Bradley; Nyberg, Lisa M; Patel, Keyur; Tillmann, Hans L; Noviello, Stephanie; Koury, Kenneth; Pedicone, Lisa; Brass, Clifford A; Albrecht, Janice K; Goldstein, David B; McHutchison, John G
ISI:000272340600060
ISSN: 0270-9139
CID: 2570182

ONCE DAILY NARLAPREVIR (SCH 900518) IN COMBINATION WITH PEGINTRON (TM) (PEGINTERFERON ALFA-2B)/RIBAVIRIN FOR TREATMENT-NAiVE SUBJECTS WITH GENOTYPE-1 CHC: INTERIM RESULTS FROM NEXT-1, A PHASE 2A STUDY [Meeting Abstract]

Vierling, John M; Poordad, Fred; Lawitz, Eric; Ghalib, Reem H; Lee, William M; Ravendhran, Natarajan; Galati, Joseph S; Bacon, Bruce R; Flamm, Steven L; Balart, Luis A; Freilich, Bradley; Schiff, Eugene R; Jacobson, Ira M; Kwo, Paul Y; Gordon, Stuart C; Sulkowski, Mark S; Boparai, Navdeep; Chaudhri, Eirum I; Brass, Clifford; Hughes, Eric A; Albrecht, Janice K
ISI:000272340600059
ISSN: 0270-9139
CID: 2570172

Does Markedly Elevated ALT Correlate with the Presence of Steatohepatitis or Advanced Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease? [Meeting Abstract]

Calo, Delia; Gambarin-Gelwan, Maya; Cavell, Lianne; Edlin, Brian; Duddempudi, Anupama; Jacobson, Ira
ISI:000270853600397
ISSN: 0002-9270
CID: 2570162

DECREASE IN PLATELETS, WHILE STILL WITHIN NORMAL RANGE, CORRELATE WITH INCREASE IN HEPATIC FIBROSIS IN CHRONIC HEPATITIS C INFECTION [Meeting Abstract]

Pereira, Arema A; Aden, Brandon; Gambarin-Gelwan, Maya; Marks, Kristen M; Talal, Andrew; Jacobson, Ira M
ISI:000270456001633
ISSN: 0270-9139
CID: 2570152

HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) IN GENOTYPE 1 (G1) NULL RESPONDERS TO PEG-INTERFEON ALFA-2B (P) PLUS RIBAVIRIN (R) WHEN TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY [Meeting Abstract]

Kwo, Paul Y; Lawitz, Eric; McCone, Jonathan; Schiff, Eugene R; Vierling, John M; Pound, David; Davis, Mitchell; Galati, Joseph S; Gordon, Stuart C; Ravendhran, Natarajan; Rossaro, Lorenzo; Anderson, Frank H; Jacobson, Ira M; Rubin, Raymond; Koury, Kenneth; Boparai, Navdeep; Chaudhri, Eirum I; Brass, Clifford A; Albrecht, Janice K
ISI:000270456000063
ISSN: 0270-9139
CID: 2570122

PROVE3 FINAL RESULTS AND 1-YEAR DURABILITY OF SVR WITH TELAPREVIR-BASED REGIMEN IN HEPATITIS C GENOTYPE 1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY [Meeting Abstract]

McHutchison, John G; Manns, Michael P; Muir, Andrew; Terrault, Norah; Jacobson, Ira M; Afdhal, Nezam H; Heathcote, EJenny; Zeuzem, Stefan; Reesink, Hendrik W; Bsharat, Mohammad; George, Shelley; Adda, Nathalie; Di Bisceglie, Adrian M
ISI:000270456000067
ISSN: 0270-9139
CID: 2570132